Zobrazeno 1 - 10
of 305
pro vyhledávání: '"Sender Herschorn"'
Autor:
Rano Matta, Amanda E. Hird, Erind Dvorani, Refik Saskin, Gregory J. Nason, Girish Kulkarni, Ronald T. Kodama, Sender Herschorn, Robert K. Nam
Publikováno v:
Cancer Medicine, Vol 9, Iss 19, Pp 6946-6953 (2020)
Abstract Background The rate of primary and secondary treatment while on active surveillance (AS) for localized prostate cancer at the general population level is unknown. Our objective was to determine the patterns of secondary treatments after prim
Externí odkaz:
https://doaj.org/article/62e897e9eeb74d919c0a9dfa94d4a2f7
Autor:
Tomas L. Griebling, Noll L. Campbell, Jeffrey Mangel, David Staskin, Sender Herschorn, Dina Elsouda, Carol R. Schermer
Publikováno v:
BMC Geriatrics, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Antimuscarinics are often used for treatment of overactive bladder (OAB), but exposure to medications such as antimuscarinics that have anticholinergic properties has been linked to adverse cognitive effects. A phase 4 placebo-con
Externí odkaz:
https://doaj.org/article/5a79ca5609c64e2cb4dccd1bd49b00e5
Autor:
Ying Liu, Steven A Narod, Rano Matta, Ronald Kodama, Lesley Carr, Refik Saskin, Sender Herschorn, Robert K Nam, Amanda E Hird, Yuna Lee, Khaled Ajib, Girish S Kulkarni
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
Objectives To compare the risk of bladder cancer and bladder cancer mortality among patients with chronic bladder catheterisation (indwelling or intermittent) to patients from the general population.Design Retrospective cohort study.Setting Populatio
Externí odkaz:
https://doaj.org/article/3a4cb1be624b4595bec684adafc6c1f3
Autor:
Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R. Schermer
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB).
Externí odkaz:
https://doaj.org/article/cc7d974246bf45c68bfa0b0042f01754
Publikováno v:
Contemporary Clinical Trials Communications, Vol 4, Iss C, Pp 199-207 (2016)
Background: Patient-level data are available for 11 randomized, controlled, Phase III/Phase IV solifenacin clinical trials. Methods: Meta-analyses were conducted to interrogate the data, to broaden knowledge about solifenacin and overactive bladder (
Externí odkaz:
https://doaj.org/article/be3acbb5e4914177a86c975dd5aea436
Autor:
Andrea Tubaro, José E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke
Publikováno v:
Therapeutic Advances in Urology, Vol 9 (2017)
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a similar prevalence of storage symptoms as women. The efficacy and safety of once-daily mirabegron 50 mg was evaluated in male OAB patients from five p
Externí odkaz:
https://doaj.org/article/1e2b142f22034207a6f43fd989029b5a
Autor:
Christopher J. D. Wallis MD, Gerard Morton MD, Angela Jerath MD, Raj Satkunasviam MD, Ewa Szumacher MD, Sender Herschorn MD, Ronald T. Kodama MD, Girish S. Kulkarni MD, David Naimark MD, Robert K. Nam MD
Publikováno v:
MDM Policy & Practice, Vol 2 (2017)
Background: Patients undergoing surgery for prostate cancer who have adverse pathological findings experience high rates of recurrence. While there are data supporting adjuvant radiotherapy compared to a wait-and-watch strategy to reduce recurrence r
Externí odkaz:
https://doaj.org/article/056dc14176be461fa2d49e7b8a19d062
Autor:
Jose E. Batista, Heinz Kölbl, Sender Herschorn, Tomasz Rechberger, Javier Cambronero, Michael Halaska, Alex Coppell, Mathilde Kaper, Moses Huang, Emad Siddiqui
Publikováno v:
Therapeutic Advances in Urology, Vol 7 (2015)
Objective: To compare the efficacy and safety of mirabegron 50 mg and solifenacin 5 mg in overactive bladder (OAB) patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy. Patients and methods: This randomized, double-bli
Externí odkaz:
https://doaj.org/article/408c607d50924e1ca9f74329f99aebe2
Autor:
Amanda E. Hird, Erind Dvorani, Refik Saskin, Urban Emmenegger, Sender Herschorn, Ronald Kodama, Girish S. Kulkarni, Robert K. Nam
Publikováno v:
Clinical Genitourinary Cancer. 21:e27-e34
To determine the prevalence and natural history of nmCRPC prior to the adoption of novel androgen receptor axis-targeting therapies(ARAT).This was a retrospective population-based cohort study of men with nmCRPC in Ontario, Canada between January 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7cb753a4ca194b8dc3262a3629c7651
https://doi.org/10.1016/j.clgc.2022.10.003
https://doi.org/10.1016/j.clgc.2022.10.003
Publikováno v:
Journal of Comparative Effectiveness Research. 11:919-925
What is this summary about? This is a summary of a study originally published in Neurourology and Urodynamics . Overactive bladder is a medical condition that causes an urgent need to urinate, which can cause accidental urination. Fesoterodine is a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12c71cf972570b4615dadbd27ddf1f71
https://doi.org/10.2217/cer-2022-0041
https://doi.org/10.2217/cer-2022-0041